Volume 21, Issue 3 (10-2018)
Hakim 2018, 21(3): 211-220 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
emami H, radfar R, emami F. Commercialization Modeling and Processes in Pharmaceutical Industry: A Case Study of Presenting an Evaluation Pattern Using Dynamic Programming Model. Hakim 2018; 21 (3) :211-220
URL: http://hakim.tums.ac.ir/article-1-1551-en.html
URL: http://hakim.tums.ac.ir/article-1-1551-en.html
1- , haemami1337@yahoo.com
Abstract: (3044 Views)
Commercialization Modeling and Processes in Pharmaceutical Industry: A Case Study of Presenting an Evaluation Pattern Using Dynamic Programming Model
Hassan Emami 1*, Reza Radfar 2, Farhad Emami 3
1Department of Health Information Management and Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Department of Industrial Management, Islamic Azad University, Science and Research Branch, Tehran, Iran
3Darou Darman Parmida Co., Tehran, Iran
Abstract
Background: There are various models and processes for commercialization in the pharmaceutical biotechnology industry. All these processes comprise three phases of scientific explorations, clinical experiments, and manufacturing, marketing, and sale. In the field of pharmaceutical biotechnology, this process is limited to opportunity identification, clinical experiments, and manufacturing, marketing, and sale. This restriction, because of existing a scientific background, provides a good opportunity for biosimilars for production.
Objectives: The aim of this research was to present an evaluation pattern to be used in the commercialization process of research outcomes by focusing on the pharmaceutical biotechnology industry.
Methods: In this descriptive-analytical research, a mixed-method exploratory approach was adopted. The statistical population included the community of experts in the pharmaceutical biotechnology industry and academic and research centers. This research used a dynamic programming model.
Results: Mathematical equations and analyzing the process network showed that among 126 sub-indices influencing the process of commercialization of R&D in pharmaceutical biotechnology, 44 factors had higher values. These factors can be considered in this process by policymakers, manufacturers, and other stakeholders in the field of pharmaceutical biotechnology.
Keywords: Evaluation; Framework; Influencing Indices in Commercialization; Pharmaceutical Biotechnology; Research and Development
Please cite this article as follows:
Emami H, Radfar R, Emami F. Commercialization Modeling and Processes in Pharmaceutical Industry:
A Case Study of Presenting an Evaluation Pattern Using Dynamic Programming Model. Hakim Health Sys Res 2018; 21(3): 211-220.
*Corresponding Author: PhD, Department of Health Information Management and Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Tel: +98-9121055900, Email: haemami@sbmu.ac.ir
Hassan Emami 1*, Reza Radfar 2, Farhad Emami 3
1Department of Health Information Management and Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Department of Industrial Management, Islamic Azad University, Science and Research Branch, Tehran, Iran
3Darou Darman Parmida Co., Tehran, Iran
Abstract
Background: There are various models and processes for commercialization in the pharmaceutical biotechnology industry. All these processes comprise three phases of scientific explorations, clinical experiments, and manufacturing, marketing, and sale. In the field of pharmaceutical biotechnology, this process is limited to opportunity identification, clinical experiments, and manufacturing, marketing, and sale. This restriction, because of existing a scientific background, provides a good opportunity for biosimilars for production.
Objectives: The aim of this research was to present an evaluation pattern to be used in the commercialization process of research outcomes by focusing on the pharmaceutical biotechnology industry.
Methods: In this descriptive-analytical research, a mixed-method exploratory approach was adopted. The statistical population included the community of experts in the pharmaceutical biotechnology industry and academic and research centers. This research used a dynamic programming model.
Results: Mathematical equations and analyzing the process network showed that among 126 sub-indices influencing the process of commercialization of R&D in pharmaceutical biotechnology, 44 factors had higher values. These factors can be considered in this process by policymakers, manufacturers, and other stakeholders in the field of pharmaceutical biotechnology.
Keywords: Evaluation; Framework; Influencing Indices in Commercialization; Pharmaceutical Biotechnology; Research and Development
Please cite this article as follows:
Emami H, Radfar R, Emami F. Commercialization Modeling and Processes in Pharmaceutical Industry:
A Case Study of Presenting an Evaluation Pattern Using Dynamic Programming Model. Hakim Health Sys Res 2018; 21(3): 211-220.
*Corresponding Author: PhD, Department of Health Information Management and Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Tel: +98-9121055900, Email: haemami@sbmu.ac.ir
Keywords: evaluation, commercialization indices, research and development, pharmaceutical biotechnology
Type of Study: Original |
Subject:
General
Received: 2016/06/27 | Accepted: 2019/03/4 | Published: 2019/03/4
Received: 2016/06/27 | Accepted: 2019/03/4 | Published: 2019/03/4
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
